Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Protagonist Therapeutics (PTGX) and MDxHealth (MDXH)...

Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), MDxHealth (MDXH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medline (MDLN), Protagonist Therapeutics (PTGX) and ...

Market Cap	$6.62B	P/E Ratio	102.04
52W High	$107.84	52W Low	$39.60
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	54.0%	52W Position	94.5%
Overall Score	52	Value Score	20
Quality Score	57	Technical Score	80

EPS Current Est	$1.02	EPS Next Est	$-1.59
EPS Growth Est	-255.9%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PTGX	$104.09	0.00%	699.46K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PTGX	$104.09	0%	699.46K
3
4
5
6

PTGX

PTGX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Protagonist Therapeutics Inc. Data in Excel

Get Protagonist Therapeutics Inc. Data in Excel